This whale alert can help traders discover the next big trading opportunities. Whales are entities w

U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaf

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today annou

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunothe

ImmunityBio, Inc. (NASDAQ: IBRX - Get Free Report) has earned an average rating of "Moderate Buy" fr

ImmunityBio Inc. (NASDAQ: IBRX) shares are soaring Friday, extending a steadily rising pattern that&

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which beat the analyst cons

ImmunityBio secures UAE marketing authorization for ANKTIVA across two cancer indications, expanding

The UAE authorization further expands ANKTIVA’s global regulatory footprint to 34 countries. The BCG

Lucid, Figma, SoundHound and Ondas are among the most heavily shorted stocks in the market right now

Jim Cramer recommended buying CAVA Group (CAVA), citing its potential and tasty, clean, and fun conc

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a B

ImmunityBio, Inc. ((

ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced preliminary res

The findings were presented at the International Society for Pharmacoeconomics and Outcomes Research

TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other

ImmunityBio shares rise after the FDA accepted ANKTIVA's sBLA for NMIBC, with Phase 2/3 data sho

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a B

Supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC w

ImmunityBio reported AUA 2026 data showing ANKTIVA plus BCG outperformed rival therapies in key blad

NAI+BCG versus Nadofaragene Results:NAI+BCG treated patients were twice as likely to achieve a compl

ImmunityBio secures exclusive U.S. rights to Japan BCG Lab's Tokyo strain of BCG, aiming to end

Five issued U.S. patents cover the combination of ImmunityBio's IL-15 receptor agonist (NAI) wit

Positive Phase III readout of National Cancer Institute-sponsored SWOG S1602 randomized clinical tri

ImmunityBio shares fall after Q1 losses misses estimates despite strong ANKTIVA sales growth and upd

ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which missed the analyst co

ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.62) per share which missed the analyst co

ImmunityBio (IBRX) stock is surging. Read why Patrick Soon-Shiong's manufacturing updates and ne

Cross-trial analyses comparing ANKTIVA + BCG with nadofaragene firadenovec-vncg and TAR-200 provide

The Avis Budget short squeeze appears to be spreading to other stocks like Beyond Meat, Opendoor and

ImmunityBio Inc. (NASDAQ:IBRX) shares are trading higher Tuesday after it launched ANKTIVA in Saudi

ImmunityBio stock rises as Q1 revenue jumps 168% and Anktiva adoption grows, even as FDA warning pro

ImmunityBio responds to FDA warning on Anktiva promotions, while NCCN update and rising sales suppor

Company initiated a comprehensive review of promotional materials and is implementing enhanced adver

Shares of ImmunityBio, Inc. (NASDAQ: IBRX) are lifting after the company announced it secured $75 mi

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, t

ImmunityBio stock dips despite Anktiva trial validation, FDA ad warning, and bullish analyst targets

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, t

ImmunityBio, Inc. (NASDAQ: IBRX) shares are trading lower after the FDA issued a warning to the comp

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/i

Macau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patie

The NCCN adds ImmunityBio Anktiva plus BCG to bladder cancer guidelines, expanding treatment use and

ImmunityBio stock rises in premarket after NK cell therapy trials show safety and scalable productio

U.S. stocks higher as Dow Jones gains 300 points; El Pollo LoCo Holdings jumps 17.6% on better-than-

BTIG analyst Jeet Mukherjee assumes ImmunityBio (NASDAQ:IBRX) with a Buy rating and announces Pr

ImmunityBio resubmits the ANKTIVA application to the FDA after a prior setback.